Kinetics of the Immune Response Profile in Guinea Pigs after Vaccination with<i>Mycobacterium bovis</i>BCG and Infection with<i>Mycobacterium tuberculosis</i>

Grover, Ajay; Taylor, Jennifer L.; Troudt, JoLynn; Keyser, Andrew; Arnett, Kimberly; Izzo, Linda; Rholl, Drew A.; Izzo, Angelo A.

doi:10.1128/iai.00704-09

Cited by 31 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…General behavior, condition of the coat, and changes to normal feeding and drinking patterns are other components of the humane end point, which is sometimes referred to as a modified Karnofsky score (Williams et al 2009). Temperature changes have been suggested as an early indicator of disease outcome (Grover et al 2009), but temperature monitoring is not adopted widely.…”

mentioning

confidence: 99%

Animal Models of Tuberculosis: Guinea Pigs

Clark

Hall

Williams

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

mentioning

confidence: 99%

Animal Models of Tuberculosis: Guinea Pigs

Clark

Hall

Williams

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

“…M. tuberculosis , H37Rv (TMCC102) used for infection of guinea pigs was grown as described previously [14]. Mycobacterium bovis BCG Pasteur (TMCC1011) strain was grown in Proskaur and Beck (P&B) medium with 0.1% Tween 80 to mid-log phase.…”

Section: Methodsmentioning

confidence: 99%

“…Cytokine mRNA expression was also determined at day 40 post-infection in the short-term challenge study, but in this study the copy number for cytokine mRNA was calculated. Samples were collected as described above and primers to amplify IFN-γ, TGF-β, TNF-α, IL-17, IL-12 [16], IL-10 [14] and IP-10 [17] for real-time PCR (Table S1 & S2) were used to determine the mRNA copy number for each cytokine (Supplementary material). The extent of mRNA induction for each cytokine was calculated using a standard curve for the specific cytokine, which consisted of a known copy number (Supplementary material).…”

Section: Methodsmentioning

confidence: 99%

Mycobacterium tuberculosis sigE mutant ST28 used as a vaccine induces protective immunity in the guinea pig model

et al. 2017

Self Cite

View full text Add to dashboard Cite

With more than 9 million new infections and 1.5 million deaths claimed every year, tuberculosis remains one of the major scourges of humankind. The only vaccine available against this disease, the attenuated strain Mycobacterium bovis, BCG is effective against severe forms of the disease in infants, but scarcely effective in protecting adults from the pulmonary form of the disease, thus not stopping transmission. Consequently, the development of an effective anti-tuberculosis vaccine is a major goal for improving global health. The most common concept is that a more effective vaccine should include a first immunization with a live vaccine followed by the administration of an acellular boosting vaccine. In this approach, the live vaccine might be either BCG or a different, more efficient attenuated strain. Recently, we showed that a Mycobacterium tuberculosis mutant missing the gene encoding for the extracellular function sigma factor SigE, is strongly attenuated and is able to induce a more effective protection from M. tuberculosis infection compared to BCG in mice. We now further characterize the protective potential of this novel strain in the guinea pig model of tuberculosis. In the guinea pig, it had limited growth but induced a Th1 immune response and was able to significantly reduce the number of colony forming units as well as prolong survival. Taken together these data provide evidence for the use of the M. tuberculosis sigE mutant as the basis for further development as a vaccine against infection.

show abstract

“…In this setting, BCG does not promote sterile clearance of M. tuberculosis but rather controls M. tuberculosis replication to different degrees. In the best-studied murine, macaque, guinea pig, and rabbit models, BCG recall responses have been shown to arrest M. tuberculosis growth several days earlier than in primary infection (89,90,(124)(125)(126)(127). Consequently, bacterial burdens and disease severity are reduced and time to death is increased.…”

Section: Lessons From Bcgmentioning

confidence: 99%

Tuberculosis Vaccines and Prevention of Infection

Hawn

Day

Scriba

et al. 2014

Microbiol Mol Biol Rev

140

View full text Add to dashboard Cite

SUMMARY Tuberculosis (TB) is a leading cause of death worldwide despite the availability of effective chemotherapy for over 60 years. Although Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination protects against active TB disease in some populations, its efficacy is suboptimal. Development of an effective TB vaccine is a top global priority that has been hampered by an incomplete understanding of protective immunity to TB. Thus far, preventing TB disease, rather than infection, has been the primary target for vaccine development. Several areas of research highlight the importance of including preinfection vaccines in the development pipeline. First, epidemiology and mathematical modeling studies indicate that a preinfection vaccine would have a high population-level impact for control of TB disease. Second, immunology studies support the rationale for targeting prevention of infection, with evidence that host responses may be more effective during acute infection than during chronic infection. Third, natural history studies indicate that resistance to TB infection occurs in a small percentage of the population. Fourth, case-control studies of BCG indicate that it may provide protection from infection. Fifth, prevention-of-infection trials would have smaller sample sizes and a shorter duration than disease prevention trials and would enable opportunities to search for correlates of immunity as well as serve as a criterion for selecting a vaccine product for testing in a larger TB disease prevention trial. Together, these points support expanding the focus of TB vaccine development efforts to include prevention of infection as a primary goal along with vaccines or other interventions that reduce the rate of transmission and reactivation.

show abstract

Kinetics of the Immune Response Profile in Guinea Pigs after Vaccination withMycobacterium bovisBCG and Infection withMycobacterium tuberculosis

Cited by 31 publications

References 39 publications

Animal Models of Tuberculosis: Guinea Pigs

Animal Models of Tuberculosis: Guinea Pigs

Mycobacterium tuberculosis sigE mutant ST28 used as a vaccine induces protective immunity in the guinea pig model

Tuberculosis Vaccines and Prevention of Infection

Contact Info

Product

Resources

About